- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04384497
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID. However, data is limited to small studies and case series on severely ill patients.
In a preliminary safety study 10 patients with severe COVID-19, defined as requiring supplementary oxygen, having fever and a duration of illness less than 11 days were treated with 200 ml of CP. CP was given as a slow infusion without obvious adverse events. Eight patients had viremia. One patient rapidly cleared the virus and recovered following CP treatment. CP infusion did not appear to clear viremia in 7/8 patients. Five of these were eventually admitted to ICU. Thus CP did not appear to cause acute toxicity but did not seem to be effective at the dose used. Viremia seemed to be a marker of a high risk of disease progression The proposed study thus aims to treat a high risk population identified by having viremia irrespective of but hopefully before they develop pulmonary injury such that they require supplementary oxygen therapy. Moreover the dose of plasma will be increased incrementally with the aim of clearing viremia as our initial study indicates that continued viremia is driving COVID-19.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 14186
- Karolinska University Hospital
-
-
Stockholm
-
Danderyd, Stockholm, Sweden, 18257
- Danderyd Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- Admitted to a study hospital
- Active COVID-19 defined as symptoms + SARS CoV-2 identified from upper or lower airway samples
- Negative pregnancy test taken before inclusion and use of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential
- Written informed consent after meeting with a study physician and ability and willingness to complete follow up
Exclusion Criteria:
- No matching plasma donor (Exact matching in both the ABO system is required)
- Unavailability of plasma
- Significant growth of alternative lower airway pathogen such as Streptococcus pneumoniae or Haemophilus influenzae in sputum
- Estimated glomerular filtration rate <60 (kidney failure stage III or more)
- Pregnancy (urinary-hcg)
- Breast feeding
- History of severe allergic reactions to foods or other substances that the donor may have been exposed to (for example severe peanut allergy)
- Inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Convalescent plasma treatment
Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions.
CP will be given as a slow infusion over 1 hour.
Patients will be monitored for adverse events, especially allergic reactions.
|
Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions).
Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy
Time Frame: Measured in the first 28 days after inclusion.
|
Progression to non-invasive or invasive ventilation or a sustained requirement of 15L of supplementary oxygen therapy in patients that are not eligible for intensive care treatment.
|
Measured in the first 28 days after inclusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: The reporting period for AEs starts at inclusion and ends at the final follow-up visit 2 months after inclusion.
|
Adverse reactions and serious adverse reactions.
The safety of the intervention will be assessed with regard to AEs, baseline medical conditions, and findings from the physical examination and laboratory tests.
Possible adverse events will be elicited using a modification and Swedish translation (appendix 6) of Common Terminology Criteria for Adverse Events v5.0 and they will be continuously reported to the sponsor.
Adverse events related to convalescent plasma therapy shall be followed to assess reversibility.
|
The reporting period for AEs starts at inclusion and ends at the final follow-up visit 2 months after inclusion.
|
Dose of plasma needed to clear viremia
Time Frame: 28 days
|
Measured as doses of convalescent plasma administered (1-7 infusions, 200ml).
|
28 days
|
Clearance of viremia
Time Frame: 6 months.
|
SARS-CoV-2 RNA detection by PCR in blood or serum.
Blood samples for immunological analyses and serology will be taken daily until discharge, on day 28, and at 6 months.
|
6 months.
|
Fever and symptoms
Time Frame: Until discharged from the hospital, up to 2 months
|
Time to resolution of fever and symptoms.
Breathing rate, peripheral oxygen saturation (measured with pulse oximetry after 20 minutes of rest), oxygen use, pulse, blood pressure, body temperature and mental state will be monitored 3 times/day while hospitalized.
|
Until discharged from the hospital, up to 2 months
|
Inflammatory parameters
Time Frame: Until discharged from the hospital, up to 2 months
|
Time to normalization of inflammatory parameters.
Blood samples for inflammatory parameters will be taken daily until normalized or discharged from the hospital.
|
Until discharged from the hospital, up to 2 months
|
Antibody response to SARS-CoV-2
Time Frame: 6 months
|
Characterization of the antibody response to SARS-CoV-2.
Blood samples for immunological analyses and serology will be taken daily until discharge, on day 28, and at 6 months.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johan Ursing, MD, PhD, Danderyd Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on SARS-CoV-2 convalescent plasma
-
Noah MerinJohns Hopkins UniversityTerminatedCovid-19 | Sars-CoV2United States
-
Ascension South East MichiganWithdrawn
-
Joakim DillnerKarolinska University Hospital; Karolinska Institutet; Danderyd HospitalCompleted
-
University Hospital, GenevaUniversity Hospital, Basel, Switzerland; Hôpital Fribourgeois; Ospedale Regionale...RecruitingCovid19 | Old Age; Debility | Immuno-DeficiencySwitzerland
-
Thomas BenfieldTerminatedCOVID | Corona Virus Infection | Viral PneumoniaDenmark
-
Orthosera Kft.University of Pecs; Semmelweis University; Hungarian National Blood Service; Humán...Recruiting
-
University of the PhilippinesTerminated
-
Medical College of WisconsinFroedtert HospitalCompletedCOVID-19United States
-
U.S. Army Medical Research and Development CommandNo longer availableTreatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)Severe Acute Respiratory Syndrome Coronavirus 2United States, Germany, Afghanistan, Djibouti, Guam, Iraq, Japan, Kuwait